Skip to main navigation
  • News & Investors

    News & Investors

    • Press Releases
    • Financial Events
    • Scientific Presentations
    • Corporate Governance
    • Financial Information
    • Stock Information
    • Analyst Coverage
    • Request Information
    • Investor FAQs
    • Investor Contact
  • Contact Us
Celsion
  • TECHNOLOGY
    • LTSL
    • TheraPlas
    • TheraSilence
  • PRODUCTS
    • ThermoDox
    • GEN-1
  • PIPELINE
    • Clinical Studies
    • Pre-clinical Programs
  • DISEASES
  • PUBLICATIONS
  • ABOUT US
    • Leadership
    • Board of Directors
    • Corporate Governance
Select Page

Press Releases

    Investor Relations

    • News & Investors
    • Press Releases
    • Financial Events
    • Scientific Presentations
    • Corporate Governance
    • Financial Information
    • Stock Information
    • Analyst Coverage
    • Request Information
    • Investor FAQs
    • Investor Contact

Press Releases

Company News

Date Title and Summary Additional Formats
Toggle Summary Feb 26, 2021 Celsion Corporation to Participate in the Virtual 33ʳᵈ Annual Roth Conference
LAWRENCEVILLE, N.J. , Feb. 26, 2021 (GLOBE NEWSWIRE) -- Celsion Corporation (NASDAQ: CLSN) , a clinical-stage development company focused on DNA-based immunotherapy and next-generation vaccines, today announced that management will be holding one-on-one meetings with investors during the Virtual 33
View HTML
PDF Version
Toggle Summary Feb 25, 2021 Celsion Corporation Provides Clinical Update on Phase I/II OVATION 2 Study with GEN-1 in Advanced Ovarian Cancer Including Encouraging Interim Resection Scores
Of 27 patients who completed interval debulking surgery, 80% of those treated with GEN-1 had an R0 resection compared with 58% of control patients, a 38% improvement To date 34 patients, or approximately one-third of the total, have been enrolled at 22 sites, including 20 patients in the treatment
View HTML
PDF Version
Toggle Summary Feb 23, 2021 Celsion Receives $2 Million Allocation Through the New Jersey Technology Business Tax Certificate Transfer (NOL) Program
Non-Dilutive Funding Strengthens Balance Sheet; Extends Current Operating Runway to Over Three Years LAWRENCEVILLE, N.J. , Feb. 23, 2021 (GLOBE NEWSWIRE) -- Celsion Corporation (NASDAQ: CLSN) , a clinical stage development company focused on DNA based immunotherapy and next generation vaccines,
View HTML
PDF Version
Toggle Summary Feb 22, 2021 Celsion Corporation Receives FDA Fast Track Designation for GEN-1 in Advanced Ovarian Cancer
Celsion’s Commitment to Promoting Immune System Solutions to Fight Life-Threatening Diseases  Granted an Accelerated Development Pathway Designation Provides Potential for an Expedited Regulatory Review. LAWRENCEVILLE, N.J. , Feb. 22, 2021 (GLOBE NEWSWIRE) -- Celsion Corporation (NASDAQ: CLSN) , a
View HTML
PDF Version
Toggle Summary Feb 12, 2021 Celsion Corporation Announces Formation of Vaccine Advisory Board
Board to provide guidance in developing the PLACCINE platform for the prevention and treatment of infectious agents, including SARS-CoV-2 LAWRENCEVILLE, N.J. , Feb. 12, 2021 (GLOBE NEWSWIRE) -- Celsion Corporation (NASDAQ: CLSN) , an oncology drug development company, today announced the formation
View HTML
PDF Version
Toggle Summary Feb 11, 2021 Celsion Corporation Issues Letter to Stockholders
Discusses Broad-based DNA Vaccine Initiative, OVATION 2 Study, and Phase III OPTIMA Study Conclusions LAWRENCEVILLE, N.J. , Feb. 11, 2021 (GLOBE NEWSWIRE) -- Celsion Corporation (NASDAQ: CLSN) , an oncology drug development company, today announced that Michael H.
View HTML
PDF Version
Toggle Summary Jan 28, 2021 Celsion Corporation Files Provisional U.S. Patent Application for a Broad Range of Next Generation DNA Vaccines
The PLACCINE Platform Technology is Conceived to Enable Rapid Development of Vaccines That Can Address a Broad Range of Infectious Agents, including SARS-Associated Coronavirus (SARS-CoV) Patent Filing Claims a Novel Composition of Multiple Antigens and Use of a Synthetic Nano Delivery Technology
View HTML
PDF Version
Toggle Summary Jan 26, 2021 CELSION CORPORATION ANNOUNCES CLOSING OF $35 MILLION REGISTERED DIRECT OFFERING OF COMMON STOCK PRICED AT-THE-MARKET UNDER NASDAQ RULES
Lawrenceville, NJ , Jan. 26, 2021 (GLOBE NEWSWIRE) -- Celsion Corporation (NASDAQ: CLSN), an oncology drug development company, today announced the closing of its previously announced registered direct offering of 25,925,925 shares of common stock at a purchase price of $1.35 per share, priced
View HTML
PDF Version
Toggle Summary Jan 22, 2021 CELSION CORPORATION ANNOUNCES $35 MILLION REGISTERED DIRECT OFFERING PRICED AT-THE-MARKET UNDER NASDAQ RULES
LAWRENCEVILLE, NJ , Jan. 22, 2021 (GLOBE NEWSWIRE) -- Celsion Corporation (NASDAQ: CLSN) (“Celsion” or the “Company”), today announced it has entered into definitive agreements with institutional investors for the purchase and sale of 25,925,925 shares of its common stock at a purchase price of
View HTML
PDF Version
Toggle Summary Nov 16, 2020 Celsion Corporation Reports Third Quarter 2020 Financial Results and Provides Business Update
         Initiates Phase II OVATION 2 Study of GEN-1 in Advanced Ovarian Cancer Continues Following Patients for Overall Survival in Phase III OPTIMA Study Conference Call Begins Today at 11:00 a.m. Eastern Time LAWRENCEVILLE, N.J , Nov. 16, 2020 (GLOBE NEWSWIRE) -- Celsion Corporation (NASDAQ:
View HTML
PDF Version

Pagination

  • Current page 1
  • Page 2
  • Page 3
  • Page 4
  • …
  • Next page Next
  • Last page Last

    Shareholder Tools

    • Printed Materials
    • Email Alerts
    • Downloads
    • RSS
    • Print
    • Search

    • Facebook
    • Google
    • LinkedIn
    • Twitter
    • RSS

Home

Technology

Products

Pipeline

Disease

Publications

News & Investors

About Us

Careers

Privacy Policy

    ThermoDox is a registered trademark of Celsion Corporation.
    TheraPlas and TheraSilence are trademarks of Celsion Corporation.
    Avastin is a registered trademark of Genentech, Inc.
    Copyright © 2021 Celsion Corporation. All rights reserved.

    Share This
    • Twitter
    • Google+
    • Facebook
    • LinkedIn